Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Short Interest Update

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN - Get Free Report) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 2,570,000 shares, an increase of 16.8% from the February 13th total of 2,200,000 shares. Approximately 2.5% of the shares of the company are short sold. Based on an average daily trading volume, of 916,800 shares, the short-interest ratio is presently 2.8 days.

Analysts Set New Price Targets

Several brokerages recently commented on REGN. Truist Financial dropped their target price on shares of Regeneron Pharmaceuticals from $1,126.00 to $1,004.00 and set a "buy" rating on the stock in a report on Wednesday, January 8th. Wells Fargo & Company cut their price objective on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an "overweight" rating for the company in a research report on Friday, January 10th. Piper Sandler lowered their target price on Regeneron Pharmaceuticals from $1,195.00 to $1,013.00 and set an "overweight" rating on the stock in a report on Monday, January 27th. Bernstein Bank dropped their price target on Regeneron Pharmaceuticals from $1,070.00 to $1,000.00 in a research report on Tuesday, February 4th. Finally, Robert W. Baird reduced their price objective on Regeneron Pharmaceuticals from $940.00 to $759.00 and set a "neutral" rating for the company in a research report on Wednesday, February 5th. One equities research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have given a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat, Regeneron Pharmaceuticals presently has an average rating of "Moderate Buy" and an average price target of $973.13.

Remove Ads

Institutional Investors Weigh In On Regeneron Pharmaceuticals

A number of large investors have recently bought and sold shares of the business. DSG Capital Advisors LLC bought a new stake in shares of Regeneron Pharmaceuticals during the fourth quarter worth $603,000. 111 Capital acquired a new position in Regeneron Pharmaceuticals during the 4th quarter worth about $378,000. NorthCrest Asset Manangement LLC grew its holdings in Regeneron Pharmaceuticals by 2.4% during the 4th quarter. NorthCrest Asset Manangement LLC now owns 11,346 shares of the biopharmaceutical company's stock worth $8,082,000 after acquiring an additional 270 shares during the last quarter. Lansforsakringar Fondforvaltning AB publ acquired a new stake in Regeneron Pharmaceuticals in the 4th quarter valued at about $29,656,000. Finally, PKO Investment Management Joint Stock Co bought a new position in shares of Regeneron Pharmaceuticals in the fourth quarter worth about $7,693,000. 83.31% of the stock is currently owned by institutional investors.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock traded down $4.14 during mid-day trading on Friday, hitting $658.48. 1,869,108 shares of the company were exchanged, compared to its average volume of 634,475. The company has a market capitalization of $71.99 billion, a PE ratio of 17.20, a price-to-earnings-growth ratio of 2.34 and a beta of 0.27. The business has a fifty day moving average of $689.43 and a 200 day moving average of $813.15. Regeneron Pharmaceuticals has a 1-year low of $642.00 and a 1-year high of $1,211.20. The company has a quick ratio of 3.95, a current ratio of 4.73 and a debt-to-equity ratio of 0.09.

Regeneron Pharmaceuticals (NASDAQ:REGN - Get Free Report) last announced its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion during the quarter, compared to analysts' expectations of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The firm's revenue for the quarter was up 10.3% on a year-over-year basis. During the same quarter last year, the company posted $11.86 EPS. As a group, sell-side analysts expect that Regeneron Pharmaceuticals will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The firm also recently announced a quarterly dividend, which was paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th were issued a $0.88 dividend. This represents a $3.52 annualized dividend and a dividend yield of 0.53%. The ex-dividend date was Thursday, February 20th. Regeneron Pharmaceuticals's payout ratio is currently 2.30%.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.